● Recruiting

CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study

Condition: T-lymphoblastic Lymphoma · T-ALL · Sponsor: Hebei Senlang Biotechnology Inc., Ltd.

PhasePhase 1

Planned participants9

Who can joinAll sexes, 18 Years to 75 Years

Healthy volunteersNo

About this study

To evaluate the tolerability and safety of SENL101 in patients with relapsed or refractory T-LBL/ALL.

This description comes directly from the study's public registry record.

Talk to the study team

Weili Zhao, Dr · 0311-82970973 · zwl_trial@163.com

Liang Huang, Dr · 0311-82970973 · tongjilunli@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

Shanghai Ruijin Hospital

Shanghai, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06136364